Última hora

INTLBrazil Dominates Haiti 3-0 to Top World Cup Group C RUUS Retirement Groups Urge Congress to Investigate Meta Over Senior Fraud Ads INIsraeli Ambassador Danny Danon Confronts UN Official Over Gaza Conflict Reports INSauce VC Set to Pocket Rs 500-550 Crore from L'Oréal's Innovist Acquisition INMeta's AI Glasses Pilot for Visually Impaired in Gujarat Raises Privacy Alarms INTargeted takedowns failed, says HC on Telegram ban AUAustralia players and coach criticize referee after loss to USA INTLAustralia confirms first mainland case of H5 bird flu in migratory bird UKWyndham Clark Leads US Open by Four Shots After Weather-Affected Second Round INMeloni Fuming After Trump Claims She Begged for Selfie INTLBrazil Dominates Haiti 3-0 to Top World Cup Group C RUUS Retirement Groups Urge Congress to Investigate Meta Over Senior Fraud Ads INIsraeli Ambassador Danny Danon Confronts UN Official Over Gaza Conflict Reports INSauce VC Set to Pocket Rs 500-550 Crore from L'Oréal's Innovist Acquisition INMeta's AI Glasses Pilot for Visually Impaired in Gujarat Raises Privacy Alarms INTargeted takedowns failed, says HC on Telegram ban AUAustralia players and coach criticize referee after loss to USA INTLAustralia confirms first mainland case of H5 bird flu in migratory bird UKWyndham Clark Leads US Open by Four Shots After Weather-Affected Second Round INMeloni Fuming After Trump Claims She Begged for Selfie

Iniciar sesión

mFlusiva

Estable2 noticias2 fuentesÚltima actualización: 12 sa önce

Temas relacionadosModerna FDA grip aşısı mRNA teknolojisi aşı onayı flu vaccine mRNA technology vaccine approval

Últimas noticias

FDA'dan Moderna'nın mRNA Teknolojili Grip Aşısına Olumlu Görüş

Salud·12 sa önceResumen IA

FDA'dan Moderna'nın mRNA Teknolojili Grip Aşısına Olumlu Görüş

FDA'nın bağımsız uzman danışma kurulu, Moderna'nın mRNA teknolojisiyle geliştirdiği yeni grip aşısı mFlusiva için olumlu görüş bildirdi. Aşı, 50-64 yaş arası yetişkinlerde tam onay, 65 yaş ve üstü kişilerde ise kullanım izni için değerlendirilecek. Nihai karar ağustos başına kadar bekleniyor.

Hürriyet Teknoloji

US Health Advisers Debate New mRNA Flu Vaccine

Salud·1 g önceResumen IA

US Health Advisers Debate New mRNA Flu Vaccine

US health advisers are reviewing Moderna's new mRNA flu vaccine, mFlusiva, for individuals 50 and older. The vaccine, similar to those used for COVID-19, showed a 27% reduction in flu cases in a study. The FDA is assessing its safety and efficacy, with a decision expected before the winter flu season.

Guardian International